{
    "organizations": [],
    "uuid": "d7078c35adc673c18e367d1ad1ad6a0e3752ac21",
    "author": "",
    "url": "https://www.reuters.com/article/brief-kamada-gets-feedback-from-fda-on-p/brief-kamada-gets-feedback-from-fda-on-proposed-phase-3-protocol-for-inhaled-alpha-1-antitrypsin-idUSASC09WR6",
    "ord_in_thread": 0,
    "title": "BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 23, 2018 / 11:50 AM / Updated 9 minutes ago BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin Reuters Staff 2 Min Read \nApril 23 (Reuters) - Kamada Ltd: \n* KAMADA RECEIVED FEEDBACK FROM FDA ON PROPOSED PHASE 3 PROTOCOL FOR INHALED ALPHA-1-ANTITRYPSIN FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE \n* KAMADA LTD - WILL NOT BE ABLE TO INITIATE PHASE 3 CLINICAL STUDY OF INHALED AAT FOR TREATMENT OF AATD IN H2 2018 UNTIL IND IS APPROVED \n* KAMADA LTD - CANNOT CURRENTLY ANTICIPATE IF AND WHEN DISCUSSIONS WITH FDA WILL MATERIALIZE INTO AN APPROVED IND \n* KAMADA LTD - HAS FORMALLY REQUESTED, EXPECTING TO PRESENT PLANNED PHASE 3 PROTOCOL IN SCIENTIFIC ADVICE MEETING WITH EMA IN Q3 2018 \n* KAMADA - INTENDS TO PROVIDE INFORMATION REQUESTED BY FDA AND DATA, AS WELL AS IMPLEMENT PROPOSED CHANGES IN STUDY PROTOCOL, DURING Q3 2018 \n* KAMADA LTD - ANTICIPATES THAT PLANNED RESPONSE WILL RESULT IN CONTINUED INTERACTION WITH FDA \n* KAMADA - IN APRIL, FDA ISSUED RESPONSE LETTER PROVIDING FURTHER GUIDANCE, ADDITIONAL QUESTIONS REGARDING PROPOSED PIVOTAL PHASE 3 PROTOCOL, \n* KAMADA - PROPOSED MODIFICATIONS, ADDITIONAL INFORMATION TO BE PROVIDED, INTENDED TO MITIGATE CONTINUED SAFETY-RELATED CONCERNS COMMUNICATED BY FDA \n* KAMADA LTD - CORRESPONDENCE INDICATED FDA HAS CONTINUED CONCERNS AND QUESTIONS RELATED TO SAFETY PROFILE OF INHALED AAT Source text for Eikon: Further company coverage:",
    "published": "2018-04-23T14:50:00.000+03:00",
    "crawled": "2018-04-23T15:04:53.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "get",
        "feedback",
        "fda",
        "proposed",
        "phase",
        "protocol",
        "inhaled",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "kamada",
        "ltd",
        "kamada",
        "received",
        "feedback",
        "fda",
        "proposed",
        "phase",
        "protocol",
        "inhaled",
        "treatment",
        "antitrypsin",
        "deficiency",
        "disease",
        "kamada",
        "ltd",
        "able",
        "initiate",
        "phase",
        "clinical",
        "study",
        "inhaled",
        "aat",
        "treatment",
        "aatd",
        "h2",
        "ind",
        "approved",
        "kamada",
        "ltd",
        "currently",
        "anticipate",
        "discussion",
        "fda",
        "materialize",
        "approved",
        "ind",
        "kamada",
        "ltd",
        "formally",
        "requested",
        "expecting",
        "present",
        "planned",
        "phase",
        "protocol",
        "scientific",
        "advice",
        "meeting",
        "ema",
        "q3",
        "kamada",
        "intends",
        "provide",
        "information",
        "requested",
        "fda",
        "data",
        "well",
        "implement",
        "proposed",
        "change",
        "study",
        "protocol",
        "q3",
        "kamada",
        "ltd",
        "anticipates",
        "planned",
        "response",
        "result",
        "continued",
        "interaction",
        "fda",
        "kamada",
        "april",
        "fda",
        "issued",
        "response",
        "letter",
        "providing",
        "guidance",
        "additional",
        "question",
        "regarding",
        "proposed",
        "pivotal",
        "phase",
        "protocol",
        "kamada",
        "proposed",
        "modification",
        "additional",
        "information",
        "provided",
        "intended",
        "mitigate",
        "continued",
        "concern",
        "communicated",
        "fda",
        "kamada",
        "ltd",
        "correspondence",
        "indicated",
        "fda",
        "continued",
        "concern",
        "question",
        "related",
        "safety",
        "profile",
        "inhaled",
        "aat",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}